Perspective reports 43% ORR, clean safety for [212Pb]VMT-α-NET in Phase 1/2a at AACR 2026

Perspective Therapeutics, Inc.

Objective response rate 43% (10/23) in Cohort 2 first half; 9 patients with deepening response since ESMO 2025.
Safety (n=64): no DLTs, no Grade 4/5 AEs, no treatment-related discontinuations, no renal complications.
18 of 25 patients (72%) progression-free in Cohorts 1 and 2 first half as of March 4, 2026 data cutoff.
Initial efficacy data from additional 23 Cohort 2 and first 8 Cohort 3 patients expected later 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.